Alvotech (NASDAQ:ALVO) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Alvotech (NASDAQ:ALVO) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $9.00 price target on the stock.

A number of other equities analysts have also recently commented on the company. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Bank of America began coverage on Alvotech in a research report on Monday, August 24th. They issued a “buy” rating and a $7.00 target price for the company. Evercore initiated coverage on shares of Alvotech in a research note on Friday, August 14th. They set an “outperform” rating on the stock. Zacks Research cut shares of Alvotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Finally, Wall Street Zen lowered shares of Alvotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.40.

Alvotech Stock Performance

NASDAQ:ALVO opened at $4.67 on Tuesday. Alvotech has a 52 week low of $2.94 and a 52 week high of $6.53. The stock’s fifty day moving average is $5.26 and its two-hundred day moving average is $4.21.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $111.60 million during the quarter, compared to analyst estimates of $125.20 million. Equities research analysts predict that Alvotech will post -0.01 EPS for the current fiscal year.

Institutional Trading of Alvotech

A number of large investors have recently modified their holdings of ALVO. State Street Corp purchased a new position in Alvotech in the third quarter valued at $594,000. Royce & Associates LP acquired a new position in Alvotech during the 3rd quarter worth $3,817,000. Commonwealth Equity Services LLC acquired a new position in Alvotech during the 3rd quarter worth $69,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Alvotech during the 3rd quarter worth about $100,000. Finally, ProShare Advisors LLC purchased a new stake in Alvotech during the 3rd quarter worth about $68,000.

Alvotech News Roundup

Investors following ALVO have been watching these news items:

• Positive Sentiment: Third-quarter product and service revenue rose 78% year over year to $58.2 million, while adjusted EBITDA more than doubled to $31.5 million. Alvotech also said it expects the fourth quarter to be the strongest in its history as supply ramps up. Alvotech earnings call highlights
• Neutral Sentiment: Alvotech maintained 2026 revenue guidance of $650 million–$700 million and EBITDA guidance of $180 million–$220 million, broadly around analyst expectations, but said results are now expected toward the lower end. Management’s forecast for a record fourth quarter depends on delivering planned shipments. Alvotech outlook
• Negative Sentiment: Third-quarter revenue of $111.6 million missed the $125.2 million consensus estimate, and the reported $0.03-per-share loss also fell short of Zacks’ $0.01-loss estimate. Nine-month adjusted revenue dropped 23% year over year, gross margin declined to 54% from 59%, and cash fell to $61.5 million from $172.4 million at year-end 2025—factors that may have outweighed the stronger quarterly EBITDA and product growth. Alvotech Q3 results

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.